Less heat, more light

Current Opinion in Lipidology

Volumn 10, Issue 3, 1999, Pages 219-223

  Rees, Alan ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; STATIN;

CLINICAL TRIAL; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CLINICAL TRIALS; CORONARY DISEASE; HUMANS; RISK FACTORS;

EID: 0032855683     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199906000-00004     Document Type: Short Survey

References (31)

1. 1 Klimov An, Nagornev VANN. Anitschkow and his contribution to the doctrine of atherosclerosis. In: Atherosclerosisis Vol. VII. Fidg NH, Nestel P (editors). Amsterdam: Elsevier Science; 1986 pp. 371-374.
2. 2 Dawber TR. The Framingham Study: the epidemiology of atherosclerotic disease. Cambridge MA: Harvard University Press; 1980.
3. 3 Smith E, Slater RS. Relationship between low density lipoprotein in aortic intima and serum lipid levels. Lancet 1972; i:463.
4. 4 Feinleib M, Kannel WB, Tedeschi CG, Landau TK, Garrison RJ. The relation of antemortem characteristics to cardiovascular findings at necroscopy. Atherosclerosis 1979; 34:145-157.
5. 5 Kachadurian AK. The inheritance of essential familial hypercholesterolaemia. Am J Med 1964; 37:402-407.
6. 6 Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol haemostasis. Science 1986; 232:34-47.
7. 7 Cholesterol lowering trials. Advice for the British Physician. Laker M, Neil A and Wood C (editors). Royal College of Physicians of London on behalf of the British Hyperlipidaemia Association 1993. Chairman's Introduction, Durrington P. 1-3.
8. 8 Law MR, Wald NJ, Thomson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308:367-373.
9. 9 Law MR, Thomson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ 1994; 308:373-379.
10. 10 Mancini GBJ. Angiographic trials of lipid lowering therapy: an update. Curr Opin Lipidol 1995; 6:379-385.
11. 11 Ericsson G-G, Hamsten A, Nilsson J, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male post infarction patients. Lancet 1996; 347:849-853.
12. 12 Multicentre Anti-Atheroma Study Investigators. Effect of simvastatin on coronary atheroma: the multicentre anti-atheroma study (MAAS). Lancet 1994; 344:633-638.
13. 13 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994; 344:1383-1389.
14. 14 Pedersen TR, Kjeksus J, Berk K, et al. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995; 345:1274-1275.
15. 15 Sacks FM, Pfeffer MA, Moye LA, et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-1009.
16. 16 The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357.
17. 17 Aspire Steering Group. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (action on secondary prevention through intervention to reduce events). Principal results. Heart 1996; 75:344-342.
18. 18 Gold AL, Rossouw JE, Santanello NC et al. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation 1995; 91:2274-2282.
19. 19 Davey-Smith G, Song F, Sheldon T. Cholesterol lowering and mortality, the importance of considering initial level of risk. BMJ 1993; 306:1367-1373.
20. 20 Holme I. An analysis of randomised controlled trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990; 82:1916-1924.
21. 21 Smith GD, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 1992; 304:431-434.
22. 22 Muldoon MF, Manuck SB, Mathews KA. Lowering cholesterol concentrations and mortality: a quantitative reveiw of primary prevention trials. BMJ 1990; 301:309-314.
23. 23 Shepherd J, Cobbe SM, Ford I, et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333:1301-1307.
24. 24 Downs GR, Clearfield M, Weiss S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TEXCAPS Air Force/Texas Coronary Atherosclerosis Study. JAMA 1998; 279:1615-1622.
25. 25 Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with Type 2 Diabetes and in non-diabetic subjects with or without prior myocardial infarction. N Engl J Med 1998; 339:229-234.
26. 26 Anderson KM, Wilson PWF, Odell PM, et al. An updated coronary risk profile: a statement for health professionals. Circulation 1991; 83:356-362.
27. 27 Wood DA, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1998; 19:1434-1503.
28. 28 Dyslipidaemia Advisory Group, on behalf of the Scientific Committee of the National Heart Foundation of New Zealand. 1996 National Heart Foundation Guidelines for the assessment and management of dyslipidaemia. NZ Med J 1996; 109:224-232.
29. 29 Haq IU, Jackson PR, Yeo WW, et al. A comparison of methods for targeting CHD risk for primary prevention (abstract). Heart 1997; 77(suppl 1):36.
30. 30 Wood D, Durrington PN, Poulter N, et al. Joint British Recommendations on prevention of coronary heart disease in clinical practice on behalf of the British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society and endorsed by the British Diabetic Association. Heart 1998; 80(suppl 2):S1-S29.
31. 31 Simpson FO. Guidelines for antihypertensive therapy: problems with a strategy based on absolute cardiovascular risk. J Hypertens 1996; 14:683-689.